Reimbursement and competitive challenges add risk for this molecular diagnostics leader.
Shares are slipping after the Board of Directors rejects a higher, unsolicited acquisition offer.
The markets finished the week on a strong note thanks to stocks like these. Find out why.
The launch of a new gene-sequencing machine made by Pacific Biosciences is underway.
It's been a tough year so far for the genomic sequencing leader's stock. Are better days ahead?
A slower-than-hoped-for launch of its latest product and a dilutive offering weighed on shares in February.
With reimbursement in place, the test maker can get into the black this year.
With the decline in HPV test sales mostly behind it, the lab-test maker is looking for a stronger 2016 and beyond.
Higher costs of revenue hurt the genomic sequencing company in the fourth quarter.
This genomic sequencing leader appears to be suffering from multiple revenue headwinds -- at least in the near term.